Aldosterone receptor antagonist and alpha-adrenergic modulating agent combination therapy for prevention or treatment of pathogenic conditions

A pharmaceutical composition for the treatment or prevention of a cardiovascular disorder comprising a first amount of an aldosterone receptor antagonist, a second amount of an alpha-adrenergic modulating agent, and one or more pharmaceutically acceptable carrier materials, wherein said first amount and said second amount together comprise a therapeutically-effective amount of said aldosterone receptor antagonist and said alpha-adrenergic modulating agent, and wherein said alpha-adrenergic modulating agent is selected from the group consisting of amosulalol, arotinolol, dapiprazole, fenspirlde, indoramin, naftopidil, nicergoline, tamsulosin, tolazoline, trimazosin, yohimbine, phenoxybenzamine, phentolamine, bunazosin, urapidil, alfuzosin, ketanserin, monatepil, SUN 9221, S-2150, apraclonidine, guanfacil, rilmenidine, and moxonidine.

A method for the treatment or prevention of a cardiovascular disorder in a subject susceptible to or afflicted with such disorder comprising administering to the subject a first amount of an aldosterone receptor antagonist and a second amount of an alpha-adrenergic modulating agent, wherein said first and second amount together comprise a therapeutically-effective amount of said aldosterone receptor antagonist and said alpha-adrenergic modulating agent, and wherein said alpha-adrenergic modulating agent is selected from the group consisting of amosulalol, arotinolol, dapiprazole, fenspirlde, indoramin, naftopidil, nicergoline, tamsulosin, tolazoline, trimazosin, yohimbine, phenoxybenzamine, phentolamine, bunazosin, urapidil, alfuzosin, ketanserin, monatepil, SUN 9221, S-2150, apraclonidine, guanfacil, rilmenidine, and moxonidine.

A pharmaceutical composition for the treatment or prevention of a cardiovascular disorder comprising a first amount of an aldosterone receptor antagonist, a second amount of an alpha-adrenergic modulating agent, and one or more pharmaceutically acceptable carrier materials, wherein said first amount and said second amount together comprise a therapeutically-effective amount of said aldosterone receptor antagonist and said alpha-adrenergic modulating agent, and wherein said composition exhibits a release profile, determined using a suitable release profile test, in which more than about 20% by weight of the aldosterone receptor antagonist is released from the composition at about four hours after initiation of the test.

A method for the treatment or prevention of a cardiovascular disorder in a subject susceptible to or afflicted with such disorder comprising administering to the subject a first amount of an aldosterone receptor antagonist and:

• a second amount of an alpha-adrenergic modulating agent, wherein said first and second amount together comprise a therapeutically-effective amount of said aldosterone receptor antagonist and said alpha-adrenergic modulating agent, and wherein the aldosterone receptor antagonist is administered to the subject in the form of a composition exhibiting a release profile, determined using a suitable release profile test, in which more than about 20% by weight of the aldosterone receptor antagonist is released from the composition at about four hours after initiation of the test.

The method of claim 86 wherein said 20-spiroxane compound is characterized by the presence of a 9α-,11α-substituted epoxy moiety.

A kit for the treatment or prevention of a cardiovascular disorder comprising an aldosterone receptor antagonist and an alpha-adrenergic modulating agent.